Zomedica Reports 14% Revenue Growth in Q2 2025 Despite Net Loss

Zomedica Corp. reported its financial results for the second quarter of 2025, revealing a net revenue of $6.964 million, a 14% increase from $6.131 million in the same period last year. For the first half of 2025, the company generated $13.464 million in revenue, up 9% from $12.393 million in the prior year. The growth in revenue was attributed to increased sales of TRUFORMA® products, the introduction of new assays, and rising consumable sales from existing PulseVet® products, alongside the recent marketing of VETIGEL®.

Despite the revenue growth, Zomedica reported a net loss of $7.398 million for the second quarter, a significant reduction from a loss of $23.931 million in the same quarter of 2024. However, the net loss for the first half of 2025 was $71.207 million, compared to $33.091 million in the previous year, primarily due to substantial impairment charges totaling $55.833 million. These impairments were linked to a decline in the company's market capitalization following the delisting of its shares from NYSE American.

The company’s total assets decreased to $136.472 million as of June 30, 2025, down from $207.360 million at the end of 2024. This decline was largely due to a reduction in goodwill and intangible assets, which were impaired by $45.556 million and $8.297 million, respectively. Zomedica's cash and cash equivalents increased to $8.129 million from $7.021 million, while total liabilities remained relatively stable at $11.115 million.

Operationally, Zomedica has focused on expanding its product offerings and enhancing its market presence. The company reported a 19% increase in selling and marketing expenses for the second quarter, reflecting investments in its sales team and marketing initiatives. The headcount in the sales department has grown as part of these efforts. Additionally, Zomedica has been actively pursuing strategic partnerships, including a recent agreement with Brisby, Inc. for the development and licensing of new products.

Looking ahead, Zomedica anticipates continued revenue growth as it ramps up its sales and marketing efforts. The company expects to maintain its focus on product development and commercialization, particularly in the diagnostics and therapeutic devices segments. However, it also acknowledges the ongoing challenges posed by market conditions and the need for careful management of its operational expenses.